Of note, the variant frequencies in the clonal tumor population (ARID2, SETD2, and TERT promoter) and in the subclonal population (NF2) were validated by targeted NGS for this patient (Additional file 1: Table S3B). The gene discussed is SETD2; the disease is neoplasm.